Biogen (NASDAQ: BIIB) has announced the appointment of Ding Weibo as the new head of its Asia-Pacific region, reporting directly to Fraser Hall, the head of Biogen’s Intercontinental Market. Ding succeeds Francis Wan in this pivotal role.
Ding Weibo brings a wealth of experience from his tenure at several multinational companies, including Bristol-Myers Squibb, Xian-Janssen, Novartis China, and Fresenius Kabi. Most recently, he served as President of Fresenius Kabi China before transitioning to Oculis, a Lausanne-based biopharmaceutical firm, on February 1, 2022. There, he held the positions of Global Chief Operating Officer (COO) and General Manager of Oculis China, focusing on developing new ophthalmic formulations for late-stage clinical treatments.
Founded in 2017, Biogen China has made significant strides in the region, launching the first spinal muscular atrophy (SMA) therapy and two innovative multiple sclerosis medications.- Flcube.com
